Akili & Shionogi partnership to bring new digital therapeutics to Asia
Category: #health  By Pankaj Singh  Date: 2019-03-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Akili & Shionogi partnership to bring new digital therapeutics to Asia
  • The new strategic partnership would see the two enterprises collaborate on the development & commercialization of digital therapeutics in crucial Asian markets.
     
  • Potential & upfront milestone payments to Akili for the Taiwan & Japan commercialization are being valued at $125 million.

Akili Interactive (Akili), an American digital medicine company, has reportedly signed a strategic partnership agreement with research-driven Japanese pharmaceutical company, Shionogi & Co., Ltd. (Shionogi) to develop & commercialize digital therapeutics across key markets in Asia.

The collaboration is reportedly to enable the commercialization of Akili’s digital medicines dubbed as AKL-T01 & the AKL-T02, in Taiwan as well as Japan.

According to a press release by Akili Interactive, the AKL-T01 is presently being reviewed by the United States Food & Drug Administration (U.S. FDA), which is determining its credibility as a potential digital therapy for children suffering from attention-deficit/hyperactivity disorder (ADHD). Meanwhile, the AKL-T02 is in the late stages of development and could be used as a potential therapy for cognitive dysfunction & related symptoms for children suffering from Autism Spectrum Disorder (ASD). Both digital treatments are delivered to the patients through immersive action videogames.

The partnership reportedly leverages both enterprise’s unique capabilities to develop a new commercial model & deploy a new class of therapy to the intended patients. Under the terms of the partnership agreement, Shionogi would be responsible for both medicine’s regulatory filings. Moreover, Shionogi would also possess the exclusive rights for the clinical development, marketing & sales of both digital therapeutics across Taiwan & Japan.

Shionogi would reportedly be making an upfront payment totaling $20 million to Akili as part of the deal. Additionally, Akili would also be eligible for substantial commercial & development milestone payments to the tune of $105 million along with significant royalties on both product’s sales in Taiwan & Japan.

According to reports, Akili would be retaining the exclusive global rights for the development & commercialization of both digital therapies across all territories outside of Taiwan & Japan.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Merck acquires Calporta Therapeutics from COI Pharmaceuticals
Merck acquires Calporta Therapeutics from COI Pharmaceuticals
By Pankaj Singh

Merck will pay up to $576 million for the acquisition   Preclinical TRPML1 has the potential to treat neurodegenerative and lysosomal disorders COI Pharmaceuticals has recently announced that Merck, also called MSD outside Canada and the U...

Personalis unveils new service for cancer whole genome sequencing
Personalis unveils new service for cancer whole genome sequencing
By Pankaj Singh

  The new launch of the services will help the company expand its oncology portfolio Personalis has been able to sequence more than 40,000 MVP samples since 2013. Personalis, Inc., a leading advanced genomics firm for cancer, recently unve...

Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
By Pankaj Singh

Celltrion Healthcare, a biopharmaceutical company, recently announced data from a study further investigating efficacy, safety, immunogenicity & pharmacokinetics of CT-P13 SC, over a period of 1-year treatment. The study focuses on the results ac...